The prevalence of hypertension in cancer patients is very high compared to the general population and varies by cancer type, being highest in colorectal cancer and lowest in breast cancer patients.
Abstract
Background
Arterial hypertension is a major cardiovascular risk factor (CVRF) associated with increased risk of cardiotoxicity in cancer patients.
Aims
The aim of this study was to determine the prevalence of hypertension in patients with newly diagnosed cancer and compare it with the prevalence in the general population.
Methods
Data were derived from the CONNECT-POL registry, the largest prospective Polish study assessing the burden of cardiovascular problems among cancer patients. Inclusion criteria were adult age and newly diagnosed breast, lung, colorectal, or prostate cancer. The occurrence of CVRF and cardiovascular diseases were recorded during a cardiology consultation.
Results
Between October 2023 and February 2025 in 11 centers 1523 patients were enrolled - 951 women, 572 men, at median age 67 (interquartile range 16) years. The most frequent CVRF was arterial hypertension, present in 949 patients (62.3%). The prevalence of hypertension reached 79.1% in colorectal, 75.1% in prostate, 69.4% in lung, and 50.1% in breast cancer. In multivariable analysis, hypertension was independently associated with age, body weight, dyslipidemia, diabetes, obesity and colon cancer compared to other cancer types. After age standardization to the structure of the WOBASZ II study, the prevalence of hypertension was higher among patients with colorectal (P = 0.045) and lung (P = 0.002) cancer compared with general population.
Conclusions
The prevalence of hypertension in cancer patients is very high compared to the general population and varies by cancer type, being highest in colorectal cancer and lowest in breast cancer patients. These results highlight the importance of routine blood pressure monitoring and encouraging home blood pressure monitoring in patients scheduled for oncological therapy.
It is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications and it is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications.
M. Mamedov, P. Skopin, A. K. Karimov· Russian Journal of Preventiv...· 0 citations
Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.
V. Dvorovy, L. Kováčová, M. Selvek et al.· European Heart Journal, Supp...· 0 citations
In this population-based cohort study, the five-year incidence of cancer following a new diagnosis of CVD was markedly high and the distribution of cancer types in this population differed from that of the general population, with a higher proportion of genitourinary cancers and a lower proportion of breast cancer.
P. Moliner, H. Morillas, A. Ricarte-Marin et al.· European Heart Journal, Supp...· 0 citations
AIMS
To assess sex-specific temporal changes in prevalence of cardiovascular risk factors (CVRF) in patients admitted for cardiovascular diseases (CVD) in Spain from 2007 to 2022.
METHODS
A retrospective, population-based analysis using the Spanish Minimum Basic Data Set, including all adults (≥18 years) hospitalised...
M. Anguita-Gámez, Antonia Sambola, R. González-Manzanares et al.· European Journal of Preventi...· 0 citations
The purpose of this study is to evaluate the different risk variables in Nellore patients with chronic renal disease. Method: From November 2025 to March 2026, a six-month prospective observational study was carried out. The patient's demographic chart and kidney health assessment questionnaire were used to gather the...
J. Ch, Deepika J, G. P et al.· Asian Journal of Hospital Ph...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.